ArticleThe journal of allergy and clinical immunology. Global2025
Serum and nasal lavage fluid eosinophil-derived neurotoxin levels and their determinants in adults.
Article in The journal of allergy and clinical immunology. Global, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Serum and Nasal Lavage Fluid Eosinophil-Derived Neurotoxin Levels in Clinically Defined Asthma Phenotypes.Clinical and translational allergy · 2026Article
- Elevated plasma eosinophil-derived neurotoxin is associated with echocardiographic pulmonary vascular involvement in stable COPD.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Eosinophil-derived neurotoxin (EDN), an eosinophil granule protein, is a candidate biomarker in asthma to reflect eosinophilic activation. Objective: We sought to characterize the distribution of serum and nasal lavage fluid (NLF) EDN levels in different adult population subgroups and assess the determinants of high EDN levels. Methods: Serum and NLF samples were collected from a population-based adult cohort study, the West Sweden Asthma Study. In total, serum EDN was measured in 2939 subjects and NLF EDN in 878 subjects, both using ImmunoCAP (Phadia AB/Thermo Fisher Scientific, Uppsala, Sweden). High EDN levels were defined as values higher than the third quartile, derived from randomly selected general adult population. Background and clinical determinants of high EDN levels were assessed in serum and NLF samples. Results: Males had higher EDN levels than females, regardless of presence of asthma or atopy. EDN levels differed by obesity and atopy, but not by age, in the random adult population. Obesity was associated with high serum EDN levels in females (adjusted odds ratio [AOR], 1.81; 95% CI, 1.08-3.04) but not in males (AOR, 1.20; 95% CI, 0.63-2.29) in the random adult population. Subjects with current asthma were more likely to have higher serum EDN levels (AOR, 1.83; 95% CI, 1.55-2.17) than those without current asthma, but not higher NLF EDN levels. Conclusions: Adults with current asthma were more likely to have higher serum, but not NLF, EDN levels than those without asthma. Although serum EDN could be a promising marker in asthma, background determinants-such as sex, obesity, and atopy-should be considered when interpreting EDN levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.